Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

This Phase 1/2 study is testing a new drug called CP-506 — which targets tumors that have defective DNA repair systems — in people with advanced or metastatic solid tumors. It can be used alone or in combination with carboplatin (chemotherapy) or immune checkpoint inhibitors. It may be especially relevant for people with BRCA mutations or similar DNA repair defects. **You may be eligible if...** - You are 18 or older with an advanced or metastatic solid tumor - Standard treatment options are no longer working or available - Your tumor has evidence of DNA repair defects (e.g., BRCA1/2 mutation), or you have certain cancer types (ovarian, breast, pancreatic, prostate, head and neck) with higher rates of these defects - You have at least one measurable tumor on scans - You are in generally good health (ECOG 0–2) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have significant heart problems (recent heart attack, severe heart failure, irregular heart rhythms) - You have active or untreated brain metastases - You have a history of autoimmune disease that required systemic treatment in the past 2 years - You have HIV, active hepatitis B or C - You have known allergies to alkylating agents - You are pregnant or breastfeeding - You have received cancer treatment within the past 4 weeks Talk to your doctor to see if this trial is right for you.